Wockhardt Ltd
NSE: WOCKPHARMA BSE: 532300
₹1346.10
(2.30)%
Tue, 03 Feb 2026, 09:14 am
Market Cap224.18B
PE Ratio-
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KAnalysis
dividend
- Unable to calculate sustainability of dividends as Wockhardt has not reported any payouts.
- Unable to evaluate Wockhardt's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Wockhardt's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Wockhardt has been profitable on average in the past, therefore cash runway is not a concern.
- Wockhardt has been profitable on average in the past, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (33.1%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 1x debt.
- Wockhardt's cash and other short term assets cover its long term commitments.
- Wockhardt's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- The level of debt compared to net worth has increased over the past 5 years (30.7% vs 77.2% today).
- Wockhardt is making a loss, therefore interest payments are not well covered by earnings.
- Wockhardt's level of debt (77.2%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Wockhardt board of directors is about average.
- Murtaza's remuneration is about average for companies of similar size in India.
- Murtaza's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Wockhardt management team is over 5 years, this suggests they are a seasoned and experienced team.
misc
- Wockhardt is not covered by any analysts.
- Wockhardt has significant price volatility in the past 3 months.
past
- Unable to compare Wockhardt's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Wockhardt does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Wockhardt used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- It is difficult to establish if Wockhardt improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
- It is difficult to establish if Wockhardt has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- Unable to compare Wockhardt's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
value
- Wockhardt's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Wockhardt's share price is below the future cash flow value, and at a substantial discount (> 40%).
- Wockhardt is good value based on assets compared to the IN Pharmaceuticals industry average.
- NSEI:WOCKPHARMA is up 10.5% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:WOCKPHARMA is up 10.5% outperforming the market in India which returned 8% over the past month.
- Wockhardt is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
- Wockhardt is loss making, we can't compare the value of its earnings to the India market.
- WOCKPHARMA underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- WOCKPHARMA underperformed the Market in India which returned -14.5% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800